ArticleCureus2025
Refractory Lupus Podocytopathy: The Role of Repeat Biopsy and Rituximab.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus podocytopathy is a rare renal manifestation of systemic lupus erythematosus (SLE) that requires treatment strategies distinct from those used for proliferative lupus nephritis. In this report, the author describes a 28-year-old man with biopsy-proven class III lupus nephritis whose proteinuria progressed despite multiple induction regimens, including high-dose corticosteroids with mycophenolate mofetil, voclosporin, and cyclophosphamide-based therapy. A repeat kidney biopsy revealed the development of lupus podocytopathy with features of the focal segmental glomerulosclerosis variant. On the basis of these findings, he was treated with a rituximab biosimilar, which led to improvements in both serologic activity and proteinuria. This case highlights the diagnostic utility of repeat kidney biopsy in refractory disease and supports the use of rituximab or its biosimilars as an effective therapeutic option for steroid-resistant lupus podocytopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.